Self-Assembly Protein Nanogels for Safer Cancer Immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27100566.
- Also identified by DOI 10.1002/adhm.201501062 and PMC identifier 5532174.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Soluble antigen-based cancer vaccines have poor retention in tissues along with suboptimal antigen processing by dendritic cells. Multiple booster doses are often needed, leading to dose-limiting systemic toxicity. A versatile, immunomodulatory, self-assembly protein nanogel vaccine is reported that induces robust immune cell response at lower antigen doses than soluble antigens, an important step towards biomaterials-based safer immunotherapy approaches.
Medical subject headings
- Antigens, Neoplasm
- Cancer Vaccines
- Immunotherapy
- Nanoparticles
- Neoplasm Proteins
- Neoplasms